Literature DB >> 15856373

An epidemiological study of the susceptibility and frequency of multiple-drug-resistant strains of Pseudomonas aeruginosa isolated at medical institutes nationwide in Japan.

Akiyoshi Tsuji1, Intetsu Kobayashi, Toyoko Oguri, Matsuhisa Inoue, Eiko Yabuuchi, Sachiko Goto.   

Abstract

The susceptibility of 3233 strains of Pseudomonas aeruginosa, isolated primarily in 2001, as agents of infection at 37 medical institutes with various specialties in seven regions of Japan (ranging from Hokkaido to Kyushu/Okinawa), to 18 antipseudomonal agents known to be active against P. aeruginosa was evaluated, in accordance with the National Committee for Clinical Laboratory Standards (NCCLS) guidelines. Of the 18 antipseudomonal agents, including some combinations of beta-lactamase inhibitors and antibacterial agents, ciprofloxacin had the lowest minimum inhibitory concentration (MIC)(50) (0.25 microg/ml) against P. aeruginosa, followed by meropenem, with an MIC(50) of 0.5 microg/ml. The MIC(50) of 7 of the examined antibacterial agents (ceftazidime, cefozopran, imipenem, biapenem, gentamicin, tobramycin, and levofloxacin) was between 1 and 2 microg/ml. Among the antipseudomonal agents tested, tobramycin showed the lowest MIC(90) (2 microg/ml), which was not significantly different from its MIC(50) (1 microg/ml). The MIC(90) of the other antibacterial agents examined ranged from 8 to 64 microg/ml and more. The susceptibility of the 3233 strains to the 12 antibacterial agents covered by the NCCLS guidelines was determined according to the standard method of the NCCLS guidelines. The frequency of strains resistant to meropenem, gentamicin, or tobramycin was relatively low (7.5%-8.3%). The frequency of strains showing intermediate to severe resistance to tobramycin was particularly low (8.0%). The frequency of strains resistant to aztreonam, imipenem, or levofloxacin was 16.7%-19.0%, about twice as high as the frequency of strains resistant to tobramycin. The susceptibility pattern of the 3233 strains (isolated from seven regions of Japan) to five antibacterial agents (ceftazidime, piperacillin, imipenem, gentamicin, and ciprofloxacin) was evaluated in relation to the regions from which they were isolated. The MIC(50) values of these antibacterial agents did not differ significantly among the regions. However, the MIC(90) values of ceftazidime and gentamicin were higher for strains isolated from the Kansai region than for strains isolated from other regions. The MIC(90) of ciprofloxacin was higher for strains isolated from the Tohoku, Kansai, and Kyushu/Okinawa regions than for strains isolated from other regions. Of the 3233 strains, 89 were classified as multiple-drug-resistant (imipenem, gentamicin, and ciprofloxacin) strains. Of these 89 strains, 42 were isolated from urine, 17 from sputum or pharyngeal mucus, 13 from pus, 8 from blood, 1 from cerebrospinal fluid, and 8 from other specimens. The frequency of multiple-drug-resistant strains was higher among strains isolated from the Tohoku and Kansai regions than in strains isolated from other regions.

Entities:  

Mesh:

Year:  2005        PMID: 15856373     DOI: 10.1007/s10156-005-0377-z

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  5 in total

Review 1.  Clinical and economic impact of common multidrug-resistant gram-negative bacilli.

Authors:  Christian G Giske; Dominique L Monnet; Otto Cars; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

2.  Outbreaks of multidrug-resistant Pseudomonas aeruginosa in community hospitals in Japan.

Authors:  Jun-Ichiro Sekiguchi; Tsukasa Asagi; Tohru Miyoshi-Akiyama; Atsushi Kasai; Yukie Mizuguchi; Minako Araake; Tomoko Fujino; Hideko Kikuchi; Satoru Sasaki; Hajime Watari; Tadashi Kojima; Hiroshi Miki; Keiji Kanemitsu; Hiroyuki Kunishima; Yoshihiro Kikuchi; Mitsuo Kaku; Hiroshi Yoshikura; Tadatoshi Kuratsuji; Teruo Kirikae
Journal:  J Clin Microbiol       Date:  2006-11-22       Impact factor: 5.948

3.  Outcome evaluation of an intervention to improve the effective and safe use of meropenem.

Authors:  Yusuke Yagi; Masafumi Okazaki; Hiromi Higaki; Megumi Nakai; Ayumu Hirata; Mitsuhiko Miyamura
Journal:  Int J Clin Pharm       Date:  2014-04-20

4.  Further increase of vancomycin-resistant Enterococcus faecium, amikacin- and fluoroquinolone-resistant Klebsiella pneumoniae, and imipenem-resistant Acinetobacter spp. in Korea: 2003 KONSAR surveillance.

Authors:  Kyungwon Lee; Ki Hyung Park; Seok Hoon Jeong; Hwan Sub Lim; Jong Hee Shin; Dongeun Yong; Gyoung-Yim Ha; Yunsop Chong
Journal:  Yonsei Med J       Date:  2006-02-28       Impact factor: 2.759

5.  Molecular analysis of the integrons of metallo-β-lactamase-producing Pseudomonas aeruginosa isolates collected by nationwide surveillance programs across Japan.

Authors:  Yoko Mano; Tomoo Saga; Yoshikazu Ishii; Ayumi Yoshizumi; Robert A Bonomo; Keizo Yamaguchi; Kazuhiro Tateda
Journal:  BMC Microbiol       Date:  2015-02-21       Impact factor: 3.605

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.